986 related articles for article (PubMed ID: 12601523)
1. Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom KE; Hellstrom I
J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.
Zhang H; Knutson KL; Hellstrom KE; Disis ML; Hellstrom I
Mol Cancer Ther; 2006 Jan; 5(1):149-55. PubMed ID: 16432173
[TBL] [Abstract][Full Text] [Related]
3. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.
Yang Y; Yang S; Ye Z; Jaffar J; Zhou Y; Cutter E; Lieber A; Hellström I; Hellström KE
Cancer Res; 2007 Mar; 67(5):2339-44. PubMed ID: 17332366
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.
Ye Z; Hellström I; Hayden-Ledbetter M; Dahlin A; Ledbetter JA; Hellström KE
Nat Med; 2002 Apr; 8(4):343-8. PubMed ID: 11927939
[TBL] [Abstract][Full Text] [Related]
8. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
9. Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.
Yang S; Yang Y; Raycraft J; Zhang H; Kanan S; Guo Y; Ronai Z; Hellstrom I; Hellstrom KE
Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4990-5. PubMed ID: 15051893
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with agonistic anti-CD137: two sides of a coin.
Sun Y; Chen JH; Fu Y
Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
[TBL] [Abstract][Full Text] [Related]
11. Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB.
Sharma S; Dominguez AL; Lustgarten J
Exp Gerontol; 2006 Jan; 41(1):78-84. PubMed ID: 16289924
[TBL] [Abstract][Full Text] [Related]
12. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
Wilcox RA; Flies DB; Zhu G; Johnson AJ; Tamada K; Chapoval AI; Strome SE; Pease LR; Chen L
J Clin Invest; 2002 Mar; 109(5):651-9. PubMed ID: 11877473
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro.
Zhang L; Wang Q; Wang X; Ding P; Song J; Ma C; Sun W
Cell Mol Immunol; 2004 Feb; 1(1):71-6. PubMed ID: 16212924
[TBL] [Abstract][Full Text] [Related]
14. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
Lynch DH
Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
[TBL] [Abstract][Full Text] [Related]
15. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
16. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.
Melero I; Johnston JV; Shufford WW; Mittler RS; Chen L
Cell Immunol; 1998 Dec; 190(2):167-72. PubMed ID: 9878117
[TBL] [Abstract][Full Text] [Related]
17. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo.
Yan X; Johnson BD; Orentas RJ
Immunology; 2004 May; 112(1):105-16. PubMed ID: 15096190
[TBL] [Abstract][Full Text] [Related]
18. Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.
Tirapu I; Arina A; Mazzolini G; Duarte M; Alfaro C; Feijoo E; Qian C; Chen L; Prieto J; Melero I
Int J Cancer; 2004 May; 110(1):51-60. PubMed ID: 15054868
[TBL] [Abstract][Full Text] [Related]
19. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
May KF; Chen L; Zheng P; Liu Y
Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.
Murillo O; Arina A; Tirapu I; Alfaro C; Mazzolini G; Palencia B; López-Diaz De Cerio A; Prieto J; Bendandi M; Melero I
Clin Cancer Res; 2003 Nov; 9(15):5454-64. PubMed ID: 14654524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
